Minnetronix Medical today announced that it has been awarded a National Institutes of Health (NIH) grant for continued study of its proprietary Neurapheresis cerebrospinal fluid treatment platform.
Akin to hemodialysis, the Neurapheresis platform is designed to rapidly remove blood cells and their cytotoxic byproducts that are released into cerebrospinal fluid following an aneurysmal subarachnoid hemorrhage.
Get the full story on our sister site, Medical Design & Outsourcing.